Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes

Introduction This retrospective study used data from a primary care database to compare two insulin products in routine clinical practice for the treatment of type 2 diabetes in the UK. Patients and methods Records were analyzed for patients with type 2 diabetes who had been initiated on biphasic insulin aspart 30 (BIAsp30) ( n =632) or biphasic isophane human insulin 30 (BHI30) ( n =762) and who had a glycated hemoglobin (HbA 1c ) measurement at baseline (up to 6 months before the index date) and end of study (6–12 months after index date). Regression analyses were used to test for a statistically significant interaction between reduction in HbA 1c from baseline to end of study and the log-transformed average daily dose (logADD) of insulin. Results With BIAsp30 a significantly lower dose of insulin (47.74 insulin units [IU]/day vs. 66.63 IU/day, P